Arsenic trioxide (As(2)O(3)): still a mystery.
Fojo
Tito
T
Medicine Branch, National Cancer Institute, Bldg. 10 Rm. 12N226, 9000 Rockville Pike, Bethesda, Maryland 20892 USA. tfojo@helix.nih.gov
Bates
Susan
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects*; D002454:Cell Differentiation; D015536:Down-Regulation; D004789:Enzyme Activation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010087:Oxides / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D014407:Tumor Cells, Cultured; D048051:p38 Mitogen-Activated Protein Kinases
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D019253:Proto-Oncogene Proteins c-bcl-2; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D000077237:Arsenic Trioxide